Smith+Nephew CFO John Rogers Resigns; Interim CFO Named
SNN is trading near its 52-week low of $28.555 (1.2% above the low).
Summary
Smith+Nephew's CFO John Rogers is resigning effective 30 September 2026. Pierre Palassian will serve as interim CFO while a search is conducted.
Key Events · Executive and Board Changes · SNN
-
CFO Resignation
John Rogers informed the Board of his intention to leave as CFO on 30 September 2026 to take an external position in the US. He steps down from the Board immediately.
-
Interim CFO Appointed
Pierre Palassian, SVP Finance and Group Controller, will serve as interim CFO until a successor is appointed. He joined Smith+Nephew in June 2017 after senior roles at AbbVie and Abbott Laboratories.
-
Departure Terms
No severance payment will be made. Rogers continues to receive salary, benefits and pension until 30 September 2026. All outstanding awards under the Annual Incentive Plan, Performance Share Plan and Restricted Share Plan lapse on 30 September 2026.
-
Activist Pressure Backdrop
The resignation follows Cevian Capital's accumulation of a 14.18% stake as of 27 July 2026, and comes two weeks after H1 results showed softer Q2 sales and a reduced full-year outlook.
Analysis · SNN · Industrial Applications And Services
CFO John Rogers is leaving on 30 September 2026 for an external US role, stepping down from the Board immediately. Pierre Palassian, SVP Finance and Group Controller, becomes interim CFO. No severance is payable and all outstanding equity awards lapse on departure. The resignation comes just two weeks after H1 results showed softer Q2 sales and a reduced full-year outlook, and amid an ongoing activist campaign by Cevian Capital, which has built a 14.18% stake. A CFO departure during a period of activist pressure and operational softness adds uncertainty around financial leadership and strategy execution.
At the time of this filing, SNN was trading at $28.89 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $28.56 to $38.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.